You are not logged in.

Cognitive effects of adjunctive N-acetyl cysteine in psychosis

Rapado-Castro, M., Dodd, S., Bush, A.I., Malhi, G.S., Skvarc, D.R., On, Z.X., Berk, M. and Dean, O.M. 2016, Cognitive effects of adjunctive N-acetyl cysteine in psychosis, Psychological medicine, First View, pp. 1-11, doi: 10.1017/S0033291716002932.

Attached Files
Name Description MIMEType Size Downloads

Title Cognitive effects of adjunctive N-acetyl cysteine in psychosis
Author(s) Rapado-Castro, M.
Dodd, S.ORCID iD for Dodd, S. orcid.org/0000-0002-7918-4636
Bush, A.I.
Malhi, G.S.
Skvarc, D.R.
On, Z.X.
Berk, M.ORCID iD for Berk, M. orcid.org/0000-0002-5554-6946
Dean, O.M.ORCID iD for Dean, O.M. orcid.org/0000-0002-2776-3935
Journal name Psychological medicine
Season First View
Start page 1
End page 11
Total pages 11
Publisher Cambridge University Press
Place of publication Cambridge, Eng.
Publication date 2016-11-29
ISSN 1469-8978
Keyword(s) N-acetyl cysteine
Cognition
glutathione
psychosis
working memory
Summary BACKGROUND: Cognitive deficits are predictors of functional outcome in patients with psychosis. While conventional antipsychotics are relatively effective on positive symptoms, their impact on negative and cognitive symptoms is limited. Recent studies have established a link between oxidative stress and neurocognitive deficits in psychosis. N-acetylcysteine (NAC), a glutathione precursor with glutamatergic properties, has shown efficacy on negative symptoms and functioning in patients with schizophrenia and bipolar disorder, respectively. However, there are few evidence-based approaches for managing cognitive impairment in psychosis. The present study aims to examine the cognitive effects of adjunctive NAC treatment in a pooled subgroup of participants with psychosis who completed neuropsychological assessment in two trials of both schizophrenia and bipolar disorder.

METHOD: A sample of 58 participants were randomized in a double fashion to receive 2 g/day of NAC (n = 27) or placebo (n = 31) for 24 weeks. Attention, working memory and executive function domains were assessed. Differences between cognitive performance at baseline and end point were examined using Wilcoxon's test. The Mann-Whitney test was used to examine the differences between the NAC and placebo groups at the end point.

RESULTS: Participants treated with NAC had significantly higher working memory performance at week 24 compared with placebo (U = 98.5, p = 0.027).

CONCLUSIONS: NAC may have an impact on cognitive performance in psychosis, as a significant improvement in working memory was observed in the NAC-treated group compared with placebo; however, these preliminary data require replication. Glutamatergic compounds such as NAC may constitute a step towards the development of useful therapies for cognitive impairment in psychosis.
Language eng
DOI 10.1017/S0033291716002932
Field of Research 110319 Psychiatry (incl Psychotherapy)
1701 Psychology
1117 Public Health And Health Services
1109 Neurosciences
Socio Economic Objective 920410 Mental Health
HERDC Research category C1 Refereed article in a scholarly journal
ERA Research output type C Journal article
Copyright notice ©2016, Cambridge University Press
Persistent URL http://hdl.handle.net/10536/DRO/DU:30090261

Document type: Journal Article
Collections: Faculty of Health
School of Psychology
School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 1 times in TR Web of Science
Scopus Citation Count Cited 0 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 19 Abstract Views, 1 File Downloads  -  Detailed Statistics
Created: Fri, 16 Dec 2016, 11:13:49 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.